Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Talphera Inc TLPH

Healthcare
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the... see more

Recent & Breaking News (NDAQ:TLPH)

AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04

PR Newswire March 16, 2015

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm

PR Newswire March 13, 2015

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

PR Newswire March 9, 2015

EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against AcelRx Pharmaceuticals, Inc. - ACRX

Business Wire March 9, 2015

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. - ACRX

PR Newswire March 9, 2015

AcelRx Provides Regulatory Update on Zalviso

PR Newswire March 9, 2015

AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015

PR Newswire March 4, 2015

AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events

PR Newswire February 20, 2015

AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference

PR Newswire February 4, 2015

AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso

PR Newswire December 2, 2014

EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important December 1, 2014 Class Action Deadline- ACRX

GlobeNewswire November 21, 2014

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX

GlobeNewswire November 20, 2014

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.

Business Wire November 20, 2014

AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events

PR Newswire November 20, 2014

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

Business Wire November 19, 2014

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014

Business Wire November 17, 2014

AcelRx Pharmaceuticals Announces Zalviso(TM) Sublingual Sufentanil Data Presentation At The American Society Of Regional Anesthesia And Pain Medicine Meeting

PR Newswire November 13, 2014

AcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results

PR Newswire November 10, 2014

AcelRx Pharmaceuticals Receives International Standards Organization (ISO) 13485:2003 Certification of its Quality Management System

PR Newswire November 10, 2014

AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events

PR Newswire November 7, 2014